OCT-04-2005 09:43 From:

OCT 0 4 2005

To:USPTO

P.1/10

Telefax Transmittal Cover sheet



29160 Intervet Lane P.O. Box 318 Millsboro, DE 19966-0318 (302) 934-4327 October 4, 2005

10 pages including cover sheet.

PERSON TO: COMPANY/DEPT TO: FAX NUMBER:

Examiner P. Baskar

USPTO

571-273-8300

Group Art Unit: 1645

PERSON FROM:	COMPANY/DEPT FROM:	FAX NUMBER:

Diane Payne on behalf of William M. Blackstone

Intervet U.S. Patent

302-934-4305

Department

USSN: 10/723,123 Customer No.: 31846

Attorney Reference No.: I-1998.407 US D2

Plcase accept the documents which follow in the above-identified application:

Response to Restriction Requirement (2 pages)

Second Preliminary Amendment (7 pages)



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED, AND MAY CONTAIN PROPRIETARY INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF YOU ARE NOT THE ADDRESSEE, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION, OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECKIVED THIS COMMUNICATION IN ERROR, NOTIFY US IMMEDIATELY BY TELEPHONE (COLLECT). THANK YOU.

RECEIVED CENTRAL FAX CENTER OCT 0 4 2005

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

BY: Diana Jaylin

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In RE Application of:

Confirmation No.:

1322

Serial No.:

10/723,123

Applicant:

SCHAAP ET AL

Filed:

November 26, 2003

Group Art Unit:

1645

Examiner:

BASKAR, P.

For:

COCCIDIOSIS VACCINES

Attorney Docket:

I-1998,407 US D2

Corresponding to:

09/749,233, filed December 27, 2000

October 4, 2005

RESPONSE TO RESTRICTION REQUIREMENT

Honorable Assistant Commissioner of Patent Alexandria, Virginia 22313-145()

Sir:

In reply to the Restriction Requirement issued September 8, 2005, applicants elect with traverse the claims in Group IV directed to vaccines, claims 16-20, for examination in this application. Applicants further elect the embodiment wherein the vaccine comprises a hydrophilic polypeptide according to claim 7, and for purposes of searching elect an amino acid sequence having at least 70% homology with SEQ ID No: 3.

Attorney Docket: I-1998.407 US D2

USSN: 10/723,123

Page 1 of 2

The Commissioner is hereby authorized in this, concurrent, and further replies, to charge payment or credit any overpayment to Deposit Account No. 02-2334.

Respectfully submitted,

William M. Blackstone Attorney for Applicants Registration No. 29,772

Intervet U.S. Patent Department P.O. Box 318 29160 Intervet Lanc Millsboro, DE 19966

Tel: 302-934-4317 Tel: 410-464-0581 Fax: 302-934-4305

WMB:jsp:dap

Attorney Docket: 1-1998,407 US D2

USSN: 10/723,123

Page 2 of 2